Intraoperative and percutaneous iridium-192 high-dose-rate brachytherapy for previously irradiated lesions of the spine

详细信息    查看全文

• 作者：Michael R. Folkert ; Mark H. Bilsky ; Gil'ad N. Cohen ; Marco Zaider ; Eric Lis ; George Krol ; Ilya Laufer ; Yoshiya Yamada
• 关键词：Metastases ; Recurrent ; Reirradiation ; Spine ; Brachytherapy ; High-dose-rate
• 刊名：Brachytherapy
• 出版年：2013
• 出版时间：September-October, 2013
• 年：2013
• 卷：12
• 期：5
• 页码：449-456
• 全文大小：838 K

文摘

Purpose

Advances in stereotactic radiosurgery have improved local control of spine metastases, but local failure is still a problem and repeat irradiation is limited by normal tissue tolerance. A novel high-dose-rate (HDR) brachytherapy technique has been developed to treat these previously irradiated lesions.

Methods and Materials

Five patients with progressive disease at previously irradiated sites in the spine who were not amenable to further external beam radiation were treated. Catheters were placed intraoperatively in 2 patients and percutaneously implanted in 3 patients with image-guided techniques. Conformal plans were generated to deliver dose to target tissues and spare critical structures. Patients received single-fraction treatment using HDR iridium-192 brachytherapy.

Results

Median dose was 14 Gy (range, 12-18 Gy) with a median gross total volume D₉₀ of 75 % (range, 31-94 % ); spinal cord/cauda equina dose constraints were met. At a median followup of 9 months, no local progression of disease has been observed. Four patients had reduction in pain 1-4 weeks after treatment. No brachytherapy-related complications have been observed.

Conclusions

Intraoperative and percutaneous iridium-192 HDR spine brachytherapy techniques were not associated with complications or acute toxicity. There has been no local progression at treated sites, and most patients experienced reduction in cancer-related pain.